Flunarizine dihydrochloride is a non-selective calcium channel antagonist primarily indicated for the prophylaxis of migraine headaches, the treatment of vertigo, and the management of peripheral vascular… Read more
Flunarizine dihydrochloride is a non-selective calcium channel antagonist primarily indicated for the prophylaxis of migraine headaches, the treatment of vertigo, and the management of peripheral vascular disease. As a fluorinated derivative of cinnarizine, it also exhibits antihistamine, serotonin receptor-blocking, and dopamine D2 receptor-blocking properties. This category provides essential high-quality reference standards, including the active pharmaceutical ingredient, specified pharmacopeial and non-pharmacopeial impurities, N-oxide metabolites, and related structural analogues. These compounds are critical for pharmaceutical laboratories conducting rigorous impurity profiling, method validation, and routine quality control. By utilizing these precise analytical reference materials, researchers can ensure the accurate identification and quantification of degradation products and synthetic by-products, supporting the development of stable and compliant pharmaceutical formulations in accordance with regulatory requirements.